Artificial Immune System for Human-Relevant Vaccine Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing vaccines and drugs are inefficient and costly, relying on animal models that are expensive and poorly predictive of human responses, leading to high attrition rates and increased development costs, with limited ability to test novel vaccines due to ethical and societal constraints.
Innovation Solution
An artificial immune system integrated with a human cell-based disease model for in vitro testing, allowing the assessment of vaccine and drug efficacy using human tissues and cells, which mimics human immunity and reduces the need for animal testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal models are used for vaccine and drug testing, then the testing can be performed with established methods, but the cost increases and predictive accuracy for human responses decreases
Solution Approach 1:
The patent creates an artificial immune system that copies human immune responses in vitro using human cells and tissues. This includes using human B cells to produce antibodies, human T cells for cell-mediated immunity, and human antigen-presenting cells to mimic the human immune system's response to pathogens and vaccines, thereby providing a human-relevant model without using animal subjects.
Solution Approach 2:
The patent introduces an artificial immune system as an intermediary between traditional animal models and human clinical trials. This in vitro system using human cells serves as a mediator that can predict human immune responses more accurately than animal models while avoiding the ethical and practical limitations of animal testing.
2Productivity
If traditional animal models are used for immunotherapy development, then the testing process can proceed through established protocols, but the development time and costs increase
Solution Approach 1:
The patent extracts the essential immune response functions from whole animal systems and isolates them into specific human cell types cultured in vitro. By taking out the key immune components (B cells, T cells, antigen-presenting cells) and studying them separately in a controlled environment, the system accelerates testing while maintaining biological relevance.
Solution Approach 2:
The patent segments the immune system into distinct functional components that can be tested independently in vitro. This includes separating humoral immunity (B cells and antibodies) from cell-mediated immunity (T cells), allowing parallel testing of different immune responses and accelerating the overall evaluation process.
3Adaptability or versatility
If more vaccines are tested in humans, then novel vaccine candidates can be evaluated, but ethical and societal constraints limit the number of tests
Solution Approach 1:
The patent creates a copy of the human immune system in vitro that can be used for extensive vaccine testing without exposing human subjects to potential risks. This artificial immune system using human cells provides an ethical alternative that maintains the ability to evaluate novel vaccine candidates.
Solution Approach 2:
The patent performs preliminary immune response evaluation in the artificial in vitro system before any human clinical trials. This preliminary testing using human cells in the artificial immune system allows vaccine candidates to be screened for safety and efficacy potential, reducing the number of candidates that would need to be tested in human subjects.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising a three-dimensional matrix comprising lymphoid tissue, a three-dimensional matrix comprising epithelial and/or endothelial cells, and diseased cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.